BIOMARKER:

KRAS G13

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D